Better Therapeutics Past Earnings Performance

Past criteria checks 0/6

Better Therapeutics's earnings have been declining at an average annual rate of -32.2%, while the Healthcare Services industry saw earnings growing at 2.8% annually. Revenues have been declining at an average rate of 169.2% per year.

Key information

-32.2%

Earnings growth rate

-1.4%

EPS growth rate

Healthcare Services Industry Growth	1.7%
Revenue growth rate	-169.2%
Return on equity	n/a
Net Margin	n/a
Last Earnings Update	30 Sep 2023

Recent past performance updates

Recent updates

Better Therapeutics files for FDA approval of new type of digital therapy for diabetes

Sep 22

Better Therapeutics GAAP EPS of -$0.42 in-line

Aug 11

Better Therapeutics: App-Based Therapeutics, Doesn't Look Novel

May 12

Better Therapeutics: Pioneering Prescription Digital Therapeutics Platform For Cardiometabolic Diseases

Nov 30

Revenue & Expenses Breakdown
Beta

How Better Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:BTTX Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
30 Sep 23	-32	19	11
30 Jun 23	-37	21	14
31 Mar 23	-39	22	16
31 Dec 22	-40	22	16
30 Sep 22	-44	22	20
30 Jun 22	-45	19	21
31 Mar 22	-44	15	22
31 Dec 21	-40	11	19
30 Sep 21	-30	6	14
30 Jun 21	-19	5	9
31 Mar 21	-12	4	4
31 Dec 20	-8	3	4
31 Dec 19	-8	3	2

Quality Earnings: BTTX is currently unprofitable.

Growing Profit Margin: BTTX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BTTX is unprofitable, and losses have increased over the past 5 years at a rate of 32.2% per year.

Accelerating Growth: Unable to compare BTTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BTTX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (15.4%).

Return on Equity

High ROE: BTTX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Better Therapeutics Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Better Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Better Therapeutics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Better Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Better Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Better Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Better Therapeutics, Inc. to Report Q1, 2022 Results on May 13, 2022

Recent updates

Better Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price and Market Value of Listed Securities Requirements for Continued Listing on The Nasdaq Capital Market

Better Therapeutics Voluntarily Requests a Delisting of its Securities and Expects its Securities to Be Delisted in the Near Term

Better Therapeutics Voluntarily Requests a Delisting of its Securities and Expects its Securities to Be Delisted in the Near Term

Better Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Better Therapeutics, Inc. Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease

Better Therapeutics, Inc. announced that it has received $0.25 million in funding

Better Therapeutics Inc. Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx Is More Effective and Less Costly Than Standard of Care Alone

Better Therapeutics, Inc. Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease

Better Therapeutics Provides Non-Compliance Update

New major risk - Share price stability

Better Therapeutics, Inc. Announces CFO Changes, Effective November 27, 2023

Better Therapeutics, Inc. Announces CFO Changes, Effective November 27, 2023

New major risk - Financial position

Better Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

New major risk - Revenue and earnings growth

New major risk - Market cap size

Better Therapeutics, Inc. Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes

Better Therapeutics, Inc. Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes

Better Therapeutics, Inc. announced that it has received $2.115287 million in funding

Price target decreased by 20% to US$6.00

Better Therapeutics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New major risk - Shareholder dilution

Better Therapeutics, Inc. announced that it expects to receive $2.115287 million in funding

Better Therapeutics, Inc. announced that it expects to receive $2.115287 million in funding

Better Therapeutics, Inc. Receives Fda Authorization for Aspyrerx to Treat Adults with Type 2 Diabetes

Better Therapeutics, Inc. Receives Fda Authorization for Aspyrerx to Treat Adults with Type 2 Diabetes

Better Therapeutics, Inc. Receives Non-Compliance Notice From Nasdaq

Consensus revenue estimates increase by 33%, EPS downgraded

Better Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased by 34% to US$11.67

Better Therapeutics, Inc. Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results

High number of new and inexperienced directors

Better Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Better Therapeutics Appoints Diane Gomez-Thinnes as Chief Commercial Officer

Better Therapeutics, Inc. Submits De Novo Request to U.S. FDA for BT-001 Investigational Prescription Digital Therapy for Type 2 Diabetes

Better Therapeutics files for FDA approval of new type of digital therapy for diabetes

Head of Finance & Interim CFO recently bought US$97k worth of stock

Better Therapeutics GAAP EPS of -$0.42 in-line

Better Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Better Therapeutics, Inc. Completes Pivotal Trial of BT-001 for Type 2 Diabetes and Announces Positive Secondary Endpoint Results

Better Therapeutics, Inc. Announces Publication of the Rationale, Design and Baseline Characteristics Manuscript for Type 2 Diabetes Pivotal Trial of BT-001

Better Therapeutics, Inc. Appoints Frank Karbe as President and as Member of the Board of Directors Starting July 5, 2022

Better Therapeutics: App-Based Therapeutics, Doesn't Look Novel

Better Therapeutics, Inc. to Report Q1, 2022 Results on May 13, 2022

High number of new and inexperienced directors

Independent Director recently bought US$86k worth of stock

Better Therapeutics, Inc. Announces Positive Primary Endpoint Data from the Pivotal Clinical Trial for the company's BT-001 Prescription Digital Therapeutic

Better Therapeutics, Inc. Announces New CMS HCPCS Code for Prescription Digital Behavioral Therapies

Better Therapeutics, Inc. Enrolls First Patient in Real World Evidence Study with Colorado Prevention Center Clinical Research

Better Therapeutics: Pioneering Prescription Digital Therapeutics Platform For Cardiometabolic Diseases

Less than half of directors are independent

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta